AGN News and Press, Allergan plc From 12/16/19

DUBLIN , Dec. 16, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) is commemorating today the beginning of the 30 th anniversary celebration for BOTOX ® this year with the ringing of the New York Stock Exchange opening bell. Over the past 30 years, more than 100 million vials of ...

Have you Noticed All the Merger Announcements? I Have A feature of this stock market has been accelerated merger announcements. I don’t believe we are at historic levels but I see it accelerating recently. I have said this many times recently, the fact that M&A is going on mea...

Since the post-deal lows of $114, Allergan ( AGN ) is up over 60%. The deal hasn't boosted AbbVie ( ABBV ) to similar levels, but now isn't the time to cash out of Allergan and shift into the very cheap AbbVie. My investment thesis remains bullish on holding Allergan into the deal close ...

By a 230-192 margin, the U.S. House of Representatives has passed legislation , championed by Speaker Nancy Pelosi, aimed at corralling spiralling drug costs. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology, Tekla World Healthcare Fund, ARK Genomic Revolution Multi-Se...

Biotech investors know that simply generating some positive clinical trial data for a candidate treatment is no guarantee that the drug will make it to market. The U.S. Food and Drug Administration (FDA) looks deep before giving its approval. And when a company announces that it has received e...

Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...

Biohaven Pharmaceuticals (NYSE: BHVN) expects to announce results from its phase 3 clinical trials before the end of 2019. The company seeks to develop drugs to treat diseases of the brain, a notoriously challenging area for drug developers. However, the risk-reward ratio should be attractiv...

No matter how many times it’s been settled throughout history, one of the most basic questions in economics keeps popping up again and again, as if for the first time. Why do things cost what they cost? Once again this question is being pondered, this time by researchers in the field of...

DUBLIN , Dec. 4, 2019 /PRNewswire/ --   Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December 5 th issue of The...

Merger activity remained unchanged with three new deals announced and one deal closing. Deal Statistics: New Deals: The acquisition of TD Ameritrade Holding Corporation (AMTD) by The Charles Schwab Corporation (SCHW) for $26 billion in an all-stock deal. Under the terms of the ag...